Breast Cancer: Targets and Therapy (Jul 2023)
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Abstract
Anna Höller,1,* Bich Doan Nguyen-Sträuli,1,2,* Heike Frauchiger-Heuer,1,* Alexander Ring1– 3,* 1Department of Gynecology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland; 3Department of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Zurich, Switzerland*These authors contributed equally to this workCorrespondence: Heike Frauchiger-Heuer, Tel +41 44 255 42 37, Email [email protected]; Alexander Ring, Tel +41 76 327 8287, Email [email protected]: Luminal breast cancers are hormone receptor (estrogen and/or progesterone) positive that are further divided into HER2-negative luminal A and HER2-positive luminal B subtypes. According to currently accepted convention, they represent the most common subtypes of breast cancer, accounting for approximately 70% of cases. Biomarkers play a critical role in the functional characterization, prognostication, and therapeutic prediction, rendering them indispensable for the clinical management of invasive breast cancer. Traditional biomarkers include clinicopathological parameters, which are increasingly extended by genetic and other molecular markers, enabling the comprehensive characterization of patients with luminal breast cancer. Liquid biopsies capturing and analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are emerging technologies that envision personalized management through precision oncology. This article reviews key biomarkers in luminal breast cancer and ongoing developments.Keywords: breast cancer, luminal A and B, biomarker, circulating tumor cells, circulating tumor DNA
